Drugs targeting protein-protein interactions.
Most biological processes involve permanent and nonpermanent interactions between different proteins, and many protein complexes play a key role in various human diseases. Therefore, molecules that prevent the formation of these protein complexes could be valuable new therapeutic agents to treat these diseases. Protein interfaces have not evolved to bind low-molecular-weight molecules, as is the case with enzyme catalytic sites. It is therefore difficult to identify small compounds that inhibit protein-protein interactions. However, there is considerable diversity in the structure of protein interfaces, some of which may be more attractive than others for medicinal chemistry. One of the main challenges in drug discovery is to identify these interfaces and to exploit their properties to make marketable drugs. Herein, the properties of protein interfaces are discussed in light of their use as drug targets.
Chène
Patrick
P
Oncology Research, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland. patrick_chene@yahoo.com
D000595:Amino Acid Sequence; D015195:Drug Design; D008970:Molecular Weight; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D011485:Protein Binding; D011506:Proteins / Q000378:metabolism*
D004364:Pharmaceutical Preparations; D011506:Proteins